Navigation Links
Kiadis Pharma Announces ATIR Interim Clinical Results
Date:10/10/2007

Successful Independent Clinical Evaluation of ATIR by Dr. Velardi for

Mismatched Bone Marrow Transplantation

AMSTERDAM, Netherlands, Oct. 10 /PRNewswire/ -- Kiadis Pharma today announced interim results of a physician initiated European Phase II clinical study for its lead product ATIR. Professor Velardi from the University of Perugia in Italy presented the successful treatment of thirteen end stage blood cancer patients with a mismatched bone marrow transplantation during the 5th workshop on "Haploidentical Stem cell Transplantation" in Catania, Italy. The results are an important milestone in the development of ATIR as a revolutionary approach to provide a safe and potentially life-saving mismatched bone marrow transplantation as treatment option for end-stage blood cancer patients.

Bone marrow transplantations are currently limited because of the high risk of Graft versus Host Disease (GvHD). This is a severe and potentially life-threatening complication in which the donor immune cells recognize and attack the patient's tissues and organs. Therefore it is currently essential that the patient and donor blood systems (the human leukocyte antigens, HLA) are highly similar in order to reduce the chance of acute GvHD. As a consequence, bone marrow transplantations strongly rely on the availability of a matching donor. However, the timely availability of a matching donor is a limiting factor for many patients to receive a bone marrow transplantation. Kiadis Pharma's ATIR is under development to prevent acute GvHD by elimination of the immune cells causing acute GvHD. A successful development would enable the performance of mismatched donor transplantations, including donor immune cells that can fight infections and the cancer without causing GvHD complications. Because ATIR eliminates acute GvHD causing cells, the transplantation can be performed without the currently standard immune suppressant regime post transplantation. This
'/>"/>

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ire/ -- The general membership of the Medical,Adv...dividuals at their Annual,Awards Dinner to be hel...k. A,Lifetime Achievement Award will also be give...vertising Hall of Fame are: , Ronald Pantello, ...osition,at Sudler & Hennessey. In 1980 he lef...
(Date:11/21/2008)...s do not cause genetic damage that can lead to dis...) -- Two popular medications for treating attentio...se genetic damage linked to an increased risk for ...y, done by researchers at Duke University Medical ...ters a previous one that reported biomarkers assoc...
(Date:11/21/2008)...e/ -- In a statewide survey, 33 physicians credent...ry at Presbyterian Hospital of Dallas were honored..." Super Doctors ." , , Each year, the publi...l Media, Inc. to survey more than 38,000 medical p... you needed medical care, which doctor would you c...
(Date:11/21/2008)...ewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE:...ts to the global orthopedic device industry and ot... Moore, President and Chief Executive Officer, and...ancial Officer, are scheduled to present at the 20...The New York Palace Hotel on Wednesday, December 3...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
... early test of the first vaccine against hepatitis...kens many Asians and can spread// to soldiers or o... made from moth cells infected with an engineered ...palese Army soldiers who took all three doses. How...
...esota permission to use state money on all varieti... bar human cloning.// The amended proposal cleare...pment Committee on a 12-7 vote. Scientists are st... to find treatments or cures for spinal cord injur...
...apanese patients looking for organ transplantation...ent of foreign patients in Chinese hospitals, more...y and not sure of receiving transplants in their h... nation where surgeries are less costly and quicke...
...ken over as the Director General of Army's Medical...ent Medical College, Nagpur he was commissioned in...ning MD in Radio Diagnosis from Pune University in...ion Oncology from the prestigious Tata Memorial Ho...
Other Medicine News:
(Date:11/20/2008)...November 20 Arpida (SWX:...ugs Advisory Committee of the,U.S. Food and Drug ...,approval of intravenous iclaprim, an antibiotic ...ients with complicated skin and skin structure inf...cillin-resistant Staphylococcus,aureus (MRSA). ,...
(Date:11/20/2008)...0 Bionovo, Inc.,(Nasdaq...lts from the Phase 1B,clinical trial of their lea...ancer, BZL101, at the Society for Integrative Onco... Georgia. The Company,s oral presentation was sel...nted as a part of the Best of the,SIO Session on ...
(Date:11/20/2008)... Radius Health ("Radius") announced...n to its second institutional financing round, inc... and the total amount raised since the company,s i...onal investors participated in the financing, led ... Capital, The Wellcome Trust, HealthCare Ventures,...
(Date:11/20/2008)...e-FirstCall/ -- PAREXEL International Corporation ...cal services provider, today announced that it has...ory consulting and clinical research capabilities.... has locations throughout five important biopharma...ude Argentina, Brazil, Chile, and Mexico. This exp...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Emageon Receives Best in KLAS Cardiology PACS Award 15216 1Emageon Receives Best in KLAS Cardiology PACS Award 15216 2QMed Inc Reports Year End and Fourth Quarter Results 15213 1QMed Inc Reports Year End and Fourth Quarter Results 15213 2QMed Inc Reports Year End and Fourth Quarter Results 15213 3QMed Inc Reports Year End and Fourth Quarter Results 15213 4QMed Inc Reports Year End and Fourth Quarter Results 15213 5QMed Inc Reports Year End and Fourth Quarter Results 15213 6QMed Inc Reports Year End and Fourth Quarter Results 15213 7Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 1Best Practice Database 3A Complimentary Excerpt of Scientific Publications Strategy Study 15210 2NCPA Statement on Californias Delay of E Pedigree Implementation 15207 1NCPA Statement on Californias Delay of E Pedigree Implementation 15207 2
...LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceutic...inary results from its,phase II/III study with CB-...ea. CB-01-11 is a broad spectrum, semi-synthetic,a...t form. Through,the use of Cosmo,s MMX(tm) technol... colon, bacteria in the gastro intestinal tract,th...
...is weeks issue of Science,researchers from the Na...(NIEHS) and Umeö University in Sweden report ...hat an enzyme called,DNA polymerase epsilon plays ...st and perhaps even humans. , The study places us ...nome instability that underlie certain environment...
Other Medicine Technology:Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 2NIEHS Researchers Identify Enzyme Critical in DNA Replication 3
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
Medicine Products: